Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients Journal Article
| Authors: | Marinelli, B.; Espinet-Col, C.; Ulaner, G. A.; McArthur, H. L.; Gonen, M.; Jochelson, M.; Weber, W. A. |
| Article Title: | Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients |
| Abstract: | FDG PET/CT-based measures of tumor burden show promise to predict survival in patients with metastatic breast cancer, but the patient populations studied so far are heterogeneous. The reports may have been confounded by the markedly different prognosis of the various subtypes of breast cancer. The purpose of this study is to evaluate the correlation between tumor burden on FDG PET/CT and overall survival (OS) in patients within a defined population: metastatic triple negative breast cancer (MTNBC). FDG PET/CT scans of 47 consecutive MTNBC patients (54 +/- 12 years-old) with no other known malignancies were analyzed. A total 393 lesions were identified, and maximum standardized uptake value (SUVmax), mean SUV, metabolic tumor volume (MTV), total lesion number (TLN) and total lesion glycolysis (TLG), were measured and correlated with patient survival by Mantel-Cox tests and Cox regression analysis. At a median follow-up time of 12.4 months, 41 patients died with a median OS of 12.1 months. Patients with MTV less than 51.5 ml lived nearly three times longer (22 vs 7.1 months) than those with a higher MTV (chi(2)=21.3, P<0.0001). In a multivariate Cox regression analysis only TLN and MTV were significantly correlated with survival. Those with an MTV burden in the 75th percentile versus the 25th percentile had a hazard ratio of 6.94 (p= 0.001). In patients with MTNBC, MTV appears to be a strong prognostic factor. If validated in prospective studies, MTV may be a valuable tool for risk stratification of MTNBC patients in clinical trials and to guide patient management. |
| Keywords: | survival; chemotherapy; carboplatin; recurrence; carcinoma; volume; fdg pet/ct; outcomes; lung-cancer; association; disease; emission tomography/computed tomography; metabolic tumor; triple-negative metastatic breast cancer; breast cancer prognosis |
| Journal Title: | American Journal of Nuclear Medicine and Molecular Imaging |
| Volume: | 6 |
| Issue: | 2 |
| ISSN: | 2160-8407 |
| Publisher: | e-Century Publishing Corporation |
| Date Published: | 2016-01-01 |
| Start Page: | 120 |
| End Page: | 127 |
| Language: | English |
| ACCESSION: | WOS:000398120000002 |
| PROVIDER: | wos |
| PMCID: | PMC4858608 |
| PUBMED: | 27186439 |
| Notes: | Carina Espinet-Coll's name is misspelled on the original publication -- Article -- Source: Wos |
Citation Impact
Related MSK Work